" class="no-js "lang="en-US"> Coen Maas - Medtech Alert
Friday, April 19, 2024
Coen Maas

Coen Maas

About Coen Maas

Rare dangerous diseases are rewarding to investigate – it is exciting work. I believe that the lessons learned from these extreme and sometimes misunderstood conditions can be directly extrapolated to more prevalent diseases, including stroke, atherosclerosis, diabetes, and Alzheimer’s disease.

• Proud winner of the 2021 NVTH quiz (eternal glory ;)
• 96 publications (3750 cites; H-index 33; RCR 2.3)
• Principal supervisor of 3 completed doctoral theses; 5 ongoing (IUS Promovendi since 2021)
• 2 patents
• 50+ Invited presentations

Related Story

TargED Biopharmaceuticals Raises EUR 39 Million in Series A Financing to Bring Groundbreaking Thrombolytic Treatment to Patients

February 22 2022

TargED Biopharmaceuticals (“TargED”), a private biotechnology company focused on developing improved treatments for thrombotic diseases, […]